755 related articles for article (PubMed ID: 16421514)
41. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
42. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
43. Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo.
Millan MJ; Rivet JM; Audinot V; Gobert A; Lejeune F; Brocco M; Newman-Tancredi A; Maurel-Remy S; Bervoets K
J Pharmacol Exp Ther; 1995 Jun; 273(3):1418-27. PubMed ID: 7791116
[TBL] [Abstract][Full Text] [Related]
44. Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat.
Caine SB; Geyer MA; Swerdlow NR
Neuropsychopharmacology; 1995 Apr; 12(2):139-45. PubMed ID: 7779242
[TBL] [Abstract][Full Text] [Related]
45. Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning.
Feifel D; Priebe K; Johnstone-Miller E; Morgan CJ
Psychopharmacology (Berl); 2002 Jul; 162(2):138-46. PubMed ID: 12110991
[TBL] [Abstract][Full Text] [Related]
46. Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.
Dekeyne A; Rivet JM; Gobert A; Millan MJ
Neuropharmacology; 2001 Jun; 40(7):899-910. PubMed ID: 11378160
[TBL] [Abstract][Full Text] [Related]
47. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat.
Swerdlow NR; Keith VA; Braff DL; Geyer MA
J Pharmacol Exp Ther; 1991 Feb; 256(2):530-6. PubMed ID: 1825226
[TBL] [Abstract][Full Text] [Related]
48. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats.
Swerdlow NR; Geyer MA; Shoemaker JM; Light GA; Braff DL; Stevens KE; Sharp R; Breier M; Neary A; Auerbach PP
Neuropsychopharmacology; 2006 Mar; 31(3):506-15. PubMed ID: 16123772
[TBL] [Abstract][Full Text] [Related]
49. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.
Rauly-Lestienne I; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Cussac D
Naunyn Schmiedebergs Arch Pharmacol; 2007 Oct; 376(1-2):93-105. PubMed ID: 17786406
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation.
Sprouse JS; Reynolds LS; Braselton JP; Rollema H; Zorn SH
Neuropsychopharmacology; 1999 Nov; 21(5):622-31. PubMed ID: 10516958
[TBL] [Abstract][Full Text] [Related]
51. Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels.
Heusler P; Newman-Tancredi A; Castro-Fernandez A; Cussac D
Neuropharmacology; 2007 Mar; 52(4):1106-13. PubMed ID: 17239906
[TBL] [Abstract][Full Text] [Related]
52. F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.
Assié MB; Bardin L; Auclair A; Consul-Denjean N; Sautel F; Depoortère R; Newman-Tancredi A
Naunyn Schmiedebergs Arch Pharmacol; 2007 Jun; 375(4):241-50. PubMed ID: 17453175
[TBL] [Abstract][Full Text] [Related]
53. Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats.
Jones CK; Eberle EL; Shaw DB; McKinzie DL; Shannon HE
J Pharmacol Exp Ther; 2005 Mar; 312(3):1055-63. PubMed ID: 15574685
[TBL] [Abstract][Full Text] [Related]
54. D1 and D2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model of schizophrenia.
Hoffman DC; Donovan H
Psychopharmacology (Berl); 1994 Aug; 115(4):447-53. PubMed ID: 7871088
[TBL] [Abstract][Full Text] [Related]
55. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
Millan MJ; Iob L; Péglion JL; Dekeyne A
Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
[TBL] [Abstract][Full Text] [Related]
56. 5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes.
Odagaki Y; Toyoshima R
Clin Exp Pharmacol Physiol; 2007; 34(5-6):462-6. PubMed ID: 17439416
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating.
Gresack JE; Seymour PA; Schmidt CJ; Risbrough VB
Psychopharmacology (Berl); 2014 May; 231(10):2189-97. PubMed ID: 24363077
[TBL] [Abstract][Full Text] [Related]
58. Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation.
Bruins Slot LA; Palmier C; Tardif S; Cussac D
Neuropharmacology; 2007 Aug; 53(2):232-41. PubMed ID: 17588617
[TBL] [Abstract][Full Text] [Related]
59. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
[TBL] [Abstract][Full Text] [Related]
60. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.
Nordquist RE; Risterucci C; Moreau JL; von Kienlin M; Künnecke B; Maco M; Freichel C; Riemer C; Spooren W
Neuropharmacology; 2008 Feb; 54(2):405-16. PubMed ID: 18054053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
